HOWL (Werewolf Therapeutics) Net Income From Continuing Operations: $-34.61 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HOWL Werewolf Therapeutics Inc HOWL
18 GF Score
Price $0.42
! 2 Warning Signs
View Full Analysis

What is Werewolf Therapeutics Net Income From Continuing Operations?

Werewolf Therapeutics HOWL +0.89% 18 Net Income From Continuing Operations is $-34.61 Mil as of Jun. 2026. GuruFocus rates HOWL with a GF Score™ of 18/100. The stock has 2 warning signs investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Werewolf Therapeutics's net income from continuing operations for the three months ended in Jun. 2026 was $3.67 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-34.61 Mil.

Werewolf Therapeutics Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Werewolf Therapeutics's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Werewolf Therapeutics Net Income From Continuing Operations Chart

Werewolf Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income From Continuing Operations
Get a 7-Day Free Trial -49.98 -53.81 -37.37 -70.52 -60.82

Werewolf Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.98 -16.37 -8.38 -13.53 3.67
HOWL
18GF Score
Werewolf Therapeutics Inc HOWL
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Werewolf Therapeutics Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of $-34.61 Mil mean?
Werewolf Therapeutics (HOWL) has a Net Income From Continuing Operations of $-34.61 Mil as of Jun. 2026. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Werewolf Therapeutics and its competitors.
Is Werewolf Therapeutics' Net Income From Continuing Operations too high?
Werewolf Therapeutics' current Net Income From Continuing Operations is $-34.61 Mil. Overall, Werewolf Therapeutics has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Werewolf Therapeutics' Net Income From Continuing Operations compare to CVM and MRKR?
Werewolf Therapeutics' Net Income From Continuing Operations of $-34.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Biotechnology company?
A good Net Income From Continuing Operations depends on the Biotechnology industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Werewolf Therapeutics and its competitors. Werewolf Therapeutics's current Net Income From Continuing Operations is $-34.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Werewolf Therapeutics stock overvalued right now?
Werewolf Therapeutics (HOWL) has a current Net Income From Continuing Operations of $-34.61 Mil. The current Net Income From Continuing Operations is $-34.61 Mil. Werewolf Therapeutics' overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Werewolf Therapeutics (HOWL), the current Net Income From Continuing Operations is $-34.61 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Werewolf Therapeutics Business Description

Address 200 Talcott Avenue, 2nd Floor, Watertown, MA, USA, 02472
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
18GF Score

Get the complete analysis for HOWL

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price